Alnylam Pharmaceuticals and Collaborators Present Data from Multiple Pre-Clinical and Clinical Programs at RNAi Keystone Symposium

Bookmark and Share

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics. Further, results were presented for the first-ever comprehensive analysis of “canonical” siRNAs compared to “dicer substrate” siRNAs, showing a superior performance of “canonical” siRNAs.

Back to news